| miR-370 may function as a tumor suppressor in laryngeal squamous cell carcinoma through downregulation of FoxM1, suggesting that miR-370 could serve as a novel potential maker for LSCC therapy. | laryngeal, |
| these data indicate that miRs-134 and -370 are potential tumour suppressor miRNAs and could play a fundamental role in suppressing colorectal cancer tumorigenesis through their ability to co-ordinately regulate EGFR signalling cascade by independently targeting EGFR and PIK3CA. | colorectal, |
| Study found that miR-370-3p had low expression levels in glioma tissues and that it served as a tumor suppressor by inhibiting glioma cell growth. Cell growth was inhibited by directly targeting beta-catenin and negatively regulating the expression of two genes downstream of the Wnt/beta-catenin pathway, cyclin D1 and c-myc. | glioma, |
| miRNA-370 acts as a tumor suppressor via the downregulation of PIM1 in hepatocellular carcinoma | liver, |
| Our findings suggest that miR-370 functions as an HCC tumor suppressor and regulator of IFN-alpha sensitivity and that miR-370 might be a useful prognostic marker for HCC patients. | liver, |
| CXCL12-regulated miR-370-3p functions as a tumor suppressor gene by targeting HMGA2 in nonfunctional pituitary adenomas | pituitary, |
| MicroRNA-370 functions as a tumor suppressor in hepatocellular carcinoma via inhibition of the MAPK/JNK signaling pathway by targeting BEX2 | liver, |
| MicroRNA-370 suppresses SOX12 transcription and acts as a tumor suppressor in bladder cancer | bladder, |
| miR-370 may function as a tumor suppressor by targeting FoxM1, and the epigenetic silence of miR-370 thus leads to derepression of FoxM1 expression and consequently contributes to AML development and progression. | None |
| The data suggest that miR-370 acts as an oncogene by downregulating WNK2 in breast cancer. | breast, |